Shanghai Pharmaceutical announced that in order to rationally allocate R&D resources and focus on advantageous R&D projects, the company decided to terminate clinical trials and subsequent development of the three R&D projects of the I010 project, the B002 project, and the B003 project based on a comprehensive evaluation of factors such as the future market value of the R&D project, business collaboration, and subsequent development investment.
上海医药：终止I010项目、B002项目及B003项目的临床试验及后续开发
Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of the I010, B002 and B003 projects
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.